iOnctura, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merck KGaA, funded by Merck Ventures. It is a clinical stage biotechnology company developing a pipeline of next generation, best-in-class molecules for the treatment of cancer and fibrosis.
Products, services, technology
IOA-244: a next generation PI3Kδ inhibitor.
IOA-289: a novel autotaxin (ATX) inhibitor.
iOnctura also has an early pipeline of antibody candidates.
iOnctura strives to develop differentiated and targeted therapeutic strategies based on the latest scientific insights and has strong collaborations with research and academic centers, including Cancer Research UK, the Netherlands Cancer Institute and Merck.